Live price temporarily unavailable.
Vor Biopharma (VOR) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$43.4M | −$69.0M | −$93.4M | −$126.0M | −$121.2M | −$371.6M |
| Net income | −$43.3M | −$68.9M | −$92.1M | −$117.9M | −$116.9M | −$696.0M |
| EPS (diluted) | −$92228.00 | −$42.00 | −$46.60 | −$35.00 | −$34.03 | −$70.50 |
| Balance sheet | ||||||
| Cash and equivalents | $48.5M | $119.8M | $57.7M | $31.4M | $81.9M | $396.5M |
| Total assets | $75.9M | $242.6M | $299.4M | $198.1M | $142.9M | $464.1M |
| Total liabilities | $27.6M | $26.3M | $48.8M | $47.4M | $46.2M | $628.4M |
| Shareholders' equity | −$59.1M | $216.3M | $250.6M | $150.7M | $96.7M | −$164.3M |
| Cash flow | ||||||
| Operating cash flow | −$36.3M | −$69.1M | −$85.1M | −$100.3M | −$99.7M | −$142.7M |
| Capital expenditure | $4.16M | $3.89M | $8.46M | $1.07M | $229.0K | $941.0K |
| Free cash flow | −$40.5M | −$73.0M | −$93.6M | −$101.4M | −$99.9M | −$143.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$28.5M | −$31.3M | −$33.3M | −$274.3M | −$28.1M | −$36.0M | −$35.2M | −$47.9M |
| Net income | −$27.6M | −$30.7M | −$32.5M | −$1.57B | −$812.7M | $1.72B | −$219.6M | −$62.8M |
| EPS (diluted) | −$8.05 | −$8.78 | −$5.21 | −$251.24 | −$121.63 | $307.58 | −$5.11 | −$1.16 |
| Balance sheet | ||||||||
| Cash and equivalents | $52.8M | $81.9M | $50.0M | $190.6M | $160.5M | $396.5M | $169.9M | $107.9M |
| Total assets | $116.0M | $142.9M | $109.3M | $205.4M | $176.2M | $464.1M | $506.7M | $481.1M |
| Total liabilities | $43.0M | $46.2M | $43.2M | $1.71B | $2.40B | $628.4M | $657.2M | $681.3M |
| Shareholders' equity | $73.0M | $96.7M | $66.1M | −$1.51B | −$2.23B | −$164.3M | −$150.4M | −$200.2M |
| Cash flow | ||||||||
| Operating cash flow | −$23.3M | −$24.1M | −$31.1M | −$35.2M | −$53.7M | −$22.8M | −$38.2M | −$25.4M |
| Capital expenditure | $34.0K | $72.0K | $231.0K | $152.0K | $244.0K | $314.0K | $48.0K | $120.0K |
| Free cash flow | −$23.3M | −$24.1M | −$31.3M | −$35.3M | −$53.9M | −$23.1M | −$38.3M | −$25.5M |
From Vor Biopharma's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Vor Biopharma in our feed yet.